Alpha 2.0
Login Register
» Authors » Cato Jacobs

Cato Jacobs

Explore the profile of Cato Jacobs including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 298
Followers 0
Related Specialties
Critical Care
Microbiology
Biomedical Engineering
Top 10 Co-Authors
Joost Wauters
Lore Vanderbeke
Greet Hermans
Katrien Lagrou
Philippe Meersseman
Stephanie Humblet-Baron
Alexander Wilmer
Simon Feys
Frank L van de Veerdonk
Karin Thevissen
Published In
Crit Care
Am J Respir Crit Care Med
Emerg Infect Dis
J Fungi (Basel)
Front Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
Damping excessive viral-induced IFN-γ rescues the impaired anti-Aspergillus host immune response in influenza-associated pulmonary aspergillosis
Seldeslachts L, Staels F, Gkountzinopoulou M, Jacobs C, Tielemans B, Vanhoffelen E, et al.
EBioMedicine . 2024 Oct; 108:105347. PMID: 39353282
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection in critically ill influenza patients that is of incompletely understood pathogenesis. Despite the use of contemporary therapies with antifungal and...
2.
Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis
Feys S, Cardinali-Benigni M, Lauwers H, Jacobs C, Stevaert A, Goncalves S, et al.
Am J Respir Crit Care Med . 2024 Jun; 210(10):1230-1242. PMID: 38865563
The influence of the lung bacterial microbiome, including potential pathogens, in patients with influenza-associated pulmonary aspergillosis (IAPA) or coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA) has yet to be explored. To...
3.
Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study
Feys S, Vanmassenhove S, Kraisin S, Yu K, Jacobs C, Boeckx B, et al.
Lancet Microbe . 2024 Jan; 5(3):e247-e260. PMID: 38280387
Background: COVID-19-associated pulmonary aspergillosis (CAPA) is a severe superinfection with the fungus Aspergillus affecting patients who are critically ill with COVID-19. The pathophysiology and the role of neutrophil extracellular traps...
4.
High Burden of COVID-19-Associated Pulmonary Aspergillosis in Severely Immunocompromised Patients Requiring Mechanical Ventilation
Feys S, Lagrou K, Lauwers H, Haenen K, Jacobs C, Brusselmans M, et al.
Clin Infect Dis . 2023 Sep; 78(2):361-370. PMID: 37691392
Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a frequent superinfection in critically ill patients with COVID-19 and is associated with increased mortality rates. The increasing proportion of severely...
5.
Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients
Cambier S, Beretta F, Portner N, Metzemaekers M, de Carvalho A, Martens E, et al.
Cell Mol Life Sci . 2023 Jul; 80(8):234. PMID: 37505242
The human chemokine stromal cell-derived factor-1 (SDF-1) or CXCL12 is involved in several homeostatic processes and pathologies through interaction with its cognate G protein-coupled receptor CXCR4. Recent research has shown...
6.
A Pathology-based Case Series of Influenza- and COVID-19-associated Pulmonary Aspergillosis: The Proof Is in the Tissue
Vanderbeke L, Jacobs C, Feys S, Resendiz-Sharpe A, Debaveye Y, Hermans G, et al.
Am J Respir Crit Care Med . 2023 Jun; 208(3):301-311. PMID: 37311243
Invasive pulmonary aspergillosis has emerged as a frequent coinfection in severe coronavirus disease (COVID-19), similarly to influenza, yet the clinical invasiveness is more debated. We investigated the invasive nature of...
7.
Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates
Malengier-Devlies B, Filtjens J, Ahmadzadeh K, Boeckx B, Vandenhaute J, De Visscher A, et al.
Front Immunol . 2022 Oct; 13:861251. PMID: 36275702
COVID-19 is characterised by a broad spectrum of clinical and pathological features. Natural killer (NK) cells play an important role in innate immune responses to viral infections. Here, we analysed...
8.
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study
Feys S, Goncalves S, Khan M, Choi S, Boeckx B, Chatelain D, et al.
Lancet Respir Med . 2022 Aug; 10(12):1147-1159. PMID: 36029799
Background: Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) affect about 15% of critically ill patients with influenza or COVID-19, respectively. These viral-fungal coinfections are difficult to diagnose and...
9.
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study
Van Daele R, Wauters J, Dreesen E, Boelens J, Nulens E, Lormans P, et al.
Mycoses . 2022 Apr; 65(6):656-660. PMID: 35437848
Background: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population. Methods: In this...
10.
Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis
Seldeslachts L, Jacobs C, Tielemans B, Vanhoffelen E, Van der Sloten L, Humblet-Baron S, et al.
J Fungi (Basel) . 2022 Jan; 8(1). PMID: 35049941
Influenza-associated pulmonary aspergillosis (IAPA) is a global recognized superinfection in critically ill influenza patients. Baloxavir marboxil, a cap-dependent endonuclease inhibitor, is a newly approved anti-influenza therapeutic. Although the benefits as...